Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 22:13:824616.
doi: 10.3389/fendo.2022.824616. eCollection 2022.

Alpha-Adrenergic Mechanisms in the Cardiovascular Hyperreactivity to Norepinephrine-Infusion in Essential Hypertension

Affiliations

Alpha-Adrenergic Mechanisms in the Cardiovascular Hyperreactivity to Norepinephrine-Infusion in Essential Hypertension

Lisa-Marie Walther et al. Front Endocrinol (Lausanne). .

Abstract

Aims: Essential hypertension (EHT) is characterized by cardiovascular hyperreactivity to stress but underlying mechanism are not fully understood. Here, we investigated the role of α-adrenergic receptors (α-AR) in the cardiovascular reactivity to a norepinephrine (NE)-stress reactivity-mimicking NE-infusion in essential hypertensive individuals (HT) as compared to normotensive individuals (NT).

Methods: 24 male HT and 24 male NT participated in three experimental trials on three separate days with a 1-min infusion followed by a 15-min infusion. Trials varied in infusion-substances: placebo saline (Sal)-infusions (trial-1:Sal+Sal), NE-infusion without (trial-2:Sal+NE) or with non-selective α-AR blockade by phentolamine (PHE) (trial-3:PHE+NE). NE-infusion dosage (5µg/ml/min) and duration were chosen to mimic duration and physiological effects of NE-release in reaction to established stress induction protocols. We repeatedly measured systolic (SBP) and diastolic blood pressure (DBP) as well as heart rate before, during, and after infusions.

Results: SBP and DBP reactivity to the three infusion-trials differed between HT and NT (p's≤.014). HT exhibited greater BP reactivity to NE-infusion alone compared to NT (trial-2-vs-trial-1: p's≤.033). Group differences in DBP reactivity to NE disappeared with prior PHE blockade (trial-3: p=.26), while SBP reactivity differences remained (trial-3: p=.016). Heart rate reactivity to infusion-trials did not differ between HT and NT (p=.73).

Conclusion: Our findings suggest a mediating role of α-AR in DBP hyperreactivity to NE-infusion in EHT. However, in SBP hyperreactivity to NE-infusion in EHT, the functioning of α-AR seems impaired suggesting that the SBP hyperreactivity in hypertension is not mediated by α-AR.

Keywords: alpha-adrenergic receptor blockade; cardiovascular reactivity; essential hypertension; norepinephrine-infusion; phentolamine.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Participant flow chart. BP, blood pressure; HT, hypertensive participants; HR, heart rate; n, sample size; NT, normotensive participants.
Figure 2
Figure 2
Infusion procedure and measurements. Infusion dosages: Norepinephrine: 75 µg (5 µg/ml/min); PHE: 2.5 mg. CVM, cardiovascular measurement; i.e. blood pressure and heart rate assessment; CAT, catecholamine assessment; PHE, phentolamine; post, post infusion 2.
Figure 3
Figure 3
Systolic blood pressure (SBP) reactivity to the three different substance infusion-trials (trial 1: Sal+Sal, circles; trial 2: Sal+NE, triangles; trial 3: PHE+NE, rectangles) in hypertensive participants (HT; black symbols; n = 23) and normotensive controls (NT; white symbols; n = 24) (mean ± SEM). SBP reactivity differed across the three trials between HT and NT as revealed by the calculated general linear model (interaction trials-by-group-by-time: p = .002). Pairwise trial comparisons by means of general linear models: In comparison to NT, HT displayed higher SBP reactivity to Sal+NE as compared to Sal+Sal (p = .033). Moreover, HT and NT differed in their SBP reactivity to PHE+NE as compared to Sal+Sal (p = .015) and to Sal+NE (p = .007): In NT, SBP reactivity to PHE+NE was markedly reduced as compared to Sal+NE, whereas HT showed a similar reactivity to Sal+NE and PHE+NE. Within each trial by means of repeated measures ANCOVAs: HT showed higher SBP reactivity to Sal+NE and PHE+NE (p’s ≤.038) but not to Sal+Sal (p = .21).
Figure 4
Figure 4
Diastolic blood pressure (DBP) reactivity to the three different substance infusion-trials (trial 1: Sal+Sal, circles; trial 2: Sal+NE, triangles; trial 3: PHE+NE, rectangles) in hypertensive participants (HT; black symbols; n = 23) and normotensive controls (NT; white symbols; n = 24) (mean ± SEM). DBP reactivity differed across the three trials between HT and NT as revealed by the calculated general linear model (interaction trials-by-group-by-time: p = .014). Pairwise trial comparisons by means of general linear models: In comparison to NT, HT displayed higher DBP reactivity to Sal+NE as compared to Sal+Sal (p = .007). PHE-induced α-adrenergic receptor blockade dampened reactivity to NE in both, HT and NT, resulting in similar reactivity to Sal+Sal and PHE+NE (Sal+Sal vs. PHE+NE: p = .55; Sal+NE vs. PHE+NE: p = .024). Within each trial by means of repeated measures ANCOVAs: DBP reactivity of HT and NT to did not differ to Sal+Sal and PHE+NE (p’s ≥.26) but to Sal+NE where HT exhibited higher reactivity as compared to NT (p = .034).
Figure 5
Figure 5
Heart rate (HR) reactivity to the three different substance infusion-trials (trial 1: Sal+Sal, circles; trial 2: Sal+NE, triangles; trial 3: PHE+NE, rectangles) in hypertensive participants (HT; black symbols; n = 23) and normotensive controls (NT; white symbols; n = 23) (mean ± SEM). HR reactivity across the three trials did not differ between HT and NT as revealed by the calculated general linear model (interaction trials-by-group-by-time: p = .73).

Similar articles

Cited by

References

    1. Poulter N. Global Risk of Cardiovascular Disease. Heart (2003) 89(suppl 2):ii2–5. doi: 10.1136/heart.89.suppl_2.ii2 - DOI - PMC - PubMed
    1. Carretero OA, Oparil S. Essential Hypertension. Circulation (2000) 101(3):329–35. doi: 10.1161/01.CIR.101.3.329 - DOI - PubMed
    1. Alderman MH, Ooi WL, Madhavan S, Cohen H. Blood Pressure Reactivity Predicts Myocardial Infarction Among Treated Hypertensive Patients. J Clin Epidemiol (1990) 43(9):859–66. doi: 10.1016/0895-4356(90)90069-2 - DOI - PubMed
    1. Nyklíček I, Bosch JA, Amerongen AVN. A Generalized Physiological Hyperreactivity to Acute Stressors in Hypertensives. Biol Psychol (2005) 70(1):44–51. doi: 10.1016/j.biopsycho.2004.11.013 - PubMed
    1. al’Absi M, Wittmers LE. Enhanced Adrenocortical Responses to Stress in Hypertension-Prone Men and Women. Ann Behav Med (2003) 25(1):25–33. doi: 10.1207/S15324796ABM2501_04 - DOI - PubMed

Publication types